and the Drug Safety Evaluation Center (DSEC). On 27 October 2004, the Paul Janssen Research Center, for discovery research, was inaugurated. In 2011, Johnson & Johnson subsidiary Centocor became Janssen Biotech, part of Janssen Pharmaceuticals. Also in 2011, Johnson & Johnson acquired Crucell, and assigned it to Janssen. The acquisition of Crucell provided Janssen with a disease prevention arm. By 2014, Crucell was renamed as Janssen Vaccines. In March 2015, Janssen licensed tipifarnib (a farnesyl transferase inhibitor) to Kura Oncology who will assume sole responsibility for developing and commercialising the anti-cancer drug. Later in the same month the company announced that Galapagos Pharma had regained the rights to the anti-inflammatory drug candidate GLPG1690 as well as two other compounds including GLPG1205 (a first-in-class inhibitor of GPR84). In May 2016, the company launched a collaboration MacroGenics and their preclinical cancer treatment, MGD015. The deal could net MacroGenics more than $740 million. In September 2017 it was announced that Janssen teamed up with the Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services, to create pandemic flu vaccines. BARDA is giving Janssen $43 million in the first year and $273 million over five years for the contract. One of the projects in the contract is the development of a universal flu vaccine. The intent of the vaccine would be to protect people against all or most flu strains. On 5 March 2019, the Food and Drug Administration approved Janssen's Spravato (esketamine nasal spray) for treatment-resistant major depressive disorder. This marked the first approval of a new type of antidepressant in decades. In 2021, Janssen was named as a defendant in a trial against several opioid manufacturers filed by New York Attorney General Letitia Jame. The company was later removed from the case after Johnson & Johnson agreed to a pay a $230 million settlement to New York State. Janssen Biotech The subsidiary Janssen Biotech, Inc. was founded in Philadelphia in 1979 as Centocor Biotech, Inc.''', with an initial goal of developing new diagnostic assays using monoclonal antibody technology. Centocor Biotech In 1982, Centocor transitioned into a publicly traded company. In the early 1980s, the company moved to Malvern, Pennsylvania. In 1984, Centocor opened an overseas plant in Leiden, the Netherlands. In 1997, eighteen years after its foundation, Centocor achieved its first year of operating profitability. In 1998, Centocor sold its diagnostic division to